Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

9MW 1111

Next Previous
Drug Profile

9MW 1111

Alternative Names: 9MW-1111; MW-11; MW11-h317; PD-1 monoclonal antibody - Mabwell (Shanghai) Bioscience

Latest Information Update: 25 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabwell (Shanghai) Bioscience
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 24 Apr 2023 No development reported - Phase-I for Solid tumours (Late-stage disease, Metastatic disease) in China (Parenteral) (Mabwell (Shanghai) Bioscience pipeline, April 2023)
  • 03 Sep 2020 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (Parenteral) (NCT04478461)
  • 24 Jul 2020 Mabwell (Shanghai) Bioscience plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, In adults, In the elderly, Second-line therapy or greater) in China (Parenteral), In August 2020 (NCT04478461)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top